|
|
Article: WEX Receives No Objection Letter From Health Canada for Phase III Clinical Trial in Cancer Pain
- Article from:
- CCNMatthews Newswire
- Article date:
- June 13, 2007
CopyrightCopyright 2007 CCNMatthews Newswire. Provided by ProQuest LLC. (Hide copyright information)
|
VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - June 13, 2007) - WEX
Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) is pleased to
announce that the Company has received a No Objection Letter from
Health Canada for conducting a Phase III clinical trial in cancer
pain for its lead product, Tectin(TM).
This multi-centre, randomized, double-blind, and placebo-
controlled trial (TEC-006) will include approximately 120 patients
with moderate to severe cancer-related pain. The study design is
based on the Company's knowledge and experience obtained from the WEX-
014 trial. A primary composite endpoint that evaluates pain reduction
with an improvement in quality of life will be used to define ...